LIVIVO - Search results -

Search results

Result 1 - 10 of total 169

Search options

Book ; Online: New Insights into Antithrombotic Therapy for Cardio- and Cerebrovascular Disease: From Molecular Mechanisms to Clinical Application

Cimmino, Giovanni / Cirillo, Plinio

2023

Keywords	Medicine ; Clinical & internal medicine ; P2Y12 inhibitor ; monotherapy ; percutaneous coronary intervention ; dual antiplatelet therapy ; high bleeding risk ; high on-treatment platelet reactivity ; randomized controlled trial ; left atrial appendage thrombus ; atrial fibrillation ; stroke ; oral anticoagulant ; cardiovascular diseases ; novel antithrombotic agents ; antiplatelet drugs ; anticoagulants ; hemostasis ; factor XI ; factor XI inhibitor ; thrombosis ; new drugs ; left ventricular thrombus ; anticoagulation ; anterior wall myocardial infarction ; dual therapy ; direct oral anticoagulants ; surface plasmon resonance ; metformin ; matrix metalloproteinase-9 ; plaque instability ; atherosclerosis ; cancer ; acute coronary syndrome (ACS) ; percutaneous coronary intervention (PCI) ; dual antiplatelet therapy (DAPT) ; triple antithrombotic therapy (TAT) ; atrial fibrillation (AF) ; cardiotoxicity ; aspirin ; coronary artery disease ; cerebrovascular disease ; diabetes mellitus ; essential thrombocythemia ; platelet function ; thromboxane ; gastrointestinal bleeding ; enteric-coated aspirin ; cardiovascular prevention ; P2Y12 inhibitors ; acute coronary syndrome ; clopidogrel ; prasugrel ; ticagrelor ; cangrelor ; selatogrel ; zalunfiban ; peripheral artery disease (PAD) ; antithrombotic therapy ; dual pathway inhibition (DPI) ; major adverse cardiovascular events (MACE) ; major adverse limb events (MALE) ; n/a
Language	English
Size	1 electronic resource (188 pages)
Publisher	MDPI - Multidisciplinary Digital Publishing Institute
Publishing place	Basel
Document type	Book ; Online
Note	English
HBZ-ID	HT030382249
ISBN	9783036581170 ; 3036581170
Database	ZB MED Catalogue: Medicine, Health, Nutrition, Environment, Agriculture

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: New Insights into Antithrombotic Therapy for Cardio- and Cerebrovascular Disease: From Molecular Mechanisms to Clinical Application.

Cirillo, Plinio / Cimmino, Giovanni

Journal of cardiovascular development and disease

2023 Volume 10, Issue 6

Abstract: Thrombosis has a pivotal role in the pathophysiology of acute cardiovascular events such as myocardial infarction and stroke [ ... ]. ...

Abstract	Thrombosis has a pivotal role in the pathophysiology of acute cardiovascular events such as myocardial infarction and stroke [...].
Language	English
Publishing date	2023-06-14
Publishing country	Switzerland
Document type	Editorial
ZDB-ID	2777082-5
ISSN	2308-3425 ; 2308-3425
ISSN (online)	2308-3425
ISSN	2308-3425
DOI	10.3390/jcdd10060258
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Colchicine in Athero-Thrombosis: Molecular Mechanisms and Clinical Evidence.

Cimmino, Giovanni / Loffredo, Francesco S / De Rosa, Gennaro / Cirillo, Plinio

International journal of molecular sciences

2023 Volume 24, Issue 3

Abstract: Several lines of evidence have clearly indicated that inflammation plays a pivotal role in the development of atherosclerosis and of its thrombotic complications such as acute coronary syndromes or ischemic stroke. Thus, it has been postulated that the ... ...

Abstract	Several lines of evidence have clearly indicated that inflammation plays a pivotal role in the development of atherosclerosis and of its thrombotic complications such as acute coronary syndromes or ischemic stroke. Thus, it has been postulated that the use of anti-inflammatory agents might be extremely useful to improve cardiovascular outcome. Recently, increasing attention has been reserved to one of the oldest plant-derived drugs still in use in clinical practice, colchicine that has been used as drug to treat inflammatory diseases such gout or Mediterranean fever. To date, current guidelines of the European Society of Cardiology have included colchicine as first line choice for treatment of acute and recurrent pericarditis. Moreover, several studies have investigated its role in the clinical scenarios of cardiovascular disease including chronic and acute coronary syndromes with promising results. In this review, starting from a description of the mechanism(s) involved behind its anti-inflammatory effects, we give an overview on its potential effects in atherothrombosis and finally present an updated overview of clinical evidence on the role of this drug in cardiovascular disease.
MeSH term(s)	Humans ; Colchicine/therapeutic use ; Acute Coronary Syndrome/drug therapy ; Inflammation/drug therapy ; Pericarditis/drug therapy ; Thrombosis/drug therapy
Chemical Substances	Colchicine (SML2Y3J35T)
Language	English
Publishing date	2023-01-27
Publishing country	Switzerland
Document type	Journal Article ; Review
ZDB-ID	2019364-6
ISSN	1422-0067 ; 1422-0067 ; 1661-6596
ISSN (online)	1422-0067
ISSN	1422-0067 ; 1661-6596
DOI	10.3390/ijms24032483
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Colchicine in Athero-Thrombosis

Giovanni Cimmino / Francesco S. Loffredo / Gennaro De Rosa / Plinio Cirillo

International Journal of Molecular Sciences, Vol 24, Iss 2483, p

Molecular Mechanisms and Clinical Evidence

2023 Volume 2483

Abstract	Several lines of evidence have clearly indicated that inflammation plays a pivotal role in the development of atherosclerosis and of its thrombotic complications such as acute coronary syndromes or ischemic stroke. Thus, it has been postulated that the use of anti-inflammatory agents might be extremely useful to improve cardiovascular outcome. Recently, increasing attention has been reserved to one of the oldest plant-derived drugs still in use in clinical practice, colchicine that has been used as drug to treat inflammatory diseases such gout or Mediterranean fever. To date, current guidelines of the European Society of Cardiology have included colchicine as first line choice for treatment of acute and recurrent pericarditis. Moreover, several studies have investigated its role in the clinical scenarios of cardiovascular disease including chronic and acute coronary syndromes with promising results. In this review, starting from a description of the mechanism(s) involved behind its anti-inflammatory effects, we give an overview on its potential effects in atherothrombosis and finally present an updated overview of clinical evidence on the role of this drug in cardiovascular disease.
Keywords	colchicine ; cardiovascular disease ; inflammation ; Biology (General) ; QH301-705.5 ; Chemistry ; QD1-999
Subject code	610
Language	English
Publishing date	2023-01-01T00:00:00Z
Publisher	MDPI AG
Document type	Article ; Online
Database	BASE - Bielefeld Academic Search Engine (life sciences selection)

Full text online

Full text

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Pathophysiology and mechanisms of Acute Coronary Syndromes: atherothrombosis, immune-inflammation, and beyond.

Cimmino, Giovanni / Di Serafino, Luigi / Cirillo, Plinio

Expert review of cardiovascular therapy

2022 Volume 20, Issue 5, Page(s) 351–362

Abstract: Introduction: The pathophysiology of atherosclerosis and its acute complications, such as the Acute Coronary Syndromes (ACS), is continuously under investigation. Immunity and inflammation seem to play a pivotal role in promoting formation and grow of ... ...

Abstract	Introduction: The pathophysiology of atherosclerosis and its acute complications, such as the Acute Coronary Syndromes (ACS), is continuously under investigation. Immunity and inflammation seem to play a pivotal role in promoting formation and grow of atherosclerotic plaques. At the same time, plaque rupture followed by both platelets' activation and coagulation cascade induction lead to intracoronary thrombus formation. Although these phenomena might be considered responsible of about 90% of ACS, in up to 5-10% of acute syndromes, a non-obstructive coronary artery disease (MINOCA) might be documented. This paper gives an overview on atherothrombosis and immuno-inflammation processes involved in ACS pathophysiology, also emphasizing the pathological mechanisms potentially involved in MINOCA. Areas covered: The relationship between immuno-inflammation and atherothrombosis is continuously updated by recent findings. At the same time, pathophysiology of MINOCA still remains a partially unexplored field, stimulating the research of potential links between these two aspects of ACS pathophysiology. Expert opinion: Pathophysiology of ACS has been extensively investigated; however, several gray areas still remain. MINOCA represents one of these areas. At the same time, many aspects of immune-inflammation processes are still unknown. Thus, research should be continued to shed a brighter light on both these sides of "ACS" moon.
MeSH term(s)	Acute Coronary Syndrome/etiology ; Atherosclerosis/complications ; Coronary Artery Disease/complications ; Humans ; Inflammation ; Plaque, Atherosclerotic/pathology
Language	English
Publishing date	2022-05-17
Publishing country	England
Document type	Journal Article
ZDB-ID	2192343-7
ISSN	1744-8344 ; 1477-9072
ISSN (online)	1744-8344
ISSN	1477-9072
DOI	10.1080/14779072.2022.2074836
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 6107: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Tissue factor: newer concepts in thrombosis and its role beyond thrombosis and hemostasis.

Cimmino, Giovanni / Cirillo, Plinio

Cardiovascular diagnosis and therapy

2018 Volume 8, Issue 5, Page(s) 581–593

Abstract: For many years, the attention on tissue factor (TF) in human pathophysiology has been limited to its role as initiator of extrinsic coagulation pathway. Moreover, it was described as a glycoprotein located in several tissue including vascular wall and ... ...

Abstract	For many years, the attention on tissue factor (TF) in human pathophysiology has been limited to its role as initiator of extrinsic coagulation pathway. Moreover, it was described as a glycoprotein located in several tissue including vascular wall and atherosclerotic plaque. However, in the last two decades, the discovery that TF circulates in the blood as cell-associated protein, microparticles (MPs) bound and as soluble form, is changing this old vessel-wall TF dogma. Moreover, it has been reported that TF is expressed by different cell types, even T lymphocytes and platelets, and different pathological conditions, such as acute and chronic inflammatory status, and cancer, may enhance its expression and activity. Thus, recent advances in the biology of TF have clearly indicated that beyond its known effects on blood coagulation, it is a "true surface receptor" involved in many intracellular signaling, cell-survival, gene and protein expression, proliferation, angiogenesis and tumor metastasis. Finally, therapeutic modulation of TF expression and/or activity has been tested with controversial results. This report, starting from the old point of view about TF as initiator of extrinsic coagulation pathway, briefly illustrates the more recent concepts about TF and thrombosis and finally gives an overview about its role beyond thrombosis and haemostasis focusing on the different intracellular mechanisms triggered by its activation and potentially involved in atherosclerosis.
Language	English
Publishing date	2018-05-18
Publishing country	China (Republic : 1949- )
Document type	Journal Article ; Review
ZDB-ID	2685043-6
ISSN	2223-3660 ; 2223-3652
ISSN (online)	2223-3660
ISSN	2223-3652
DOI	10.21037/cdt.2018.10.14
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Uric acid plasma levels are associated with C-reactive protein concentrations and the extent of coronary artery lesions in patients with acute coronary syndromes.

Cimmino, Giovanni / Gallinoro, Emanuele / di Serafino, Luigi / De Rosa, Gennaro / Sugraliyev, Akhmetzhan / Golino, Paolo / Cirillo, Plinio

Internal and emergency medicine

2023 Volume 18, Issue 6, Page(s) 1751–1757

Abstract: Many studies have pointed out that inflammation plays a pivotal role in pathophysiology of acute coronary syndromes (ACS) because several inflammatory molecules impair the endothelial functions in the coronary circulation and promote atherothrombotic ... ...

Abstract	Many studies have pointed out that inflammation plays a pivotal role in pathophysiology of acute coronary syndromes (ACS) because several inflammatory molecules impair the endothelial functions in the coronary circulation and promote atherothrombotic events. Recently, many clinical/experimental evidences indicate that elevated plasma levels of uric acid (UA) might be considered a risk factor for developing ACS. It has been reported that elevated UA doses impair physiologic functions of endothelial cells, shifting them toward a pro atherothrombotic phenotype. In the present manuscript, we investigated the relationship between UA plasma levels, inflammatory burden, and extension of coronary atherosclerotic disease in patients with ACS. Patients with a clinical presentation of ACS (ST-elevated and non-ST-elevated myocardial infarction) admitted to the Vanvitelli Catheterization Laboratory at Monaldi Hospital in 2019, before the COVID-19 pandemia, were retrospectively analyzed. Biochemical profile, type of ACS presentation, as well as extension of coronary atherosclerosis were assessed. A total of 132 ACS patients were included in the analysis, and grouped into 3 tertiles according to the UA values (UA < 4.72 mg/dl, UA between 4.72 and 6.15 mg/dl, and UA > 6.15 mg/dl). Patients with UA plasma levels ≥ 6.15 mg/dL showed higher levels of C-reactive protein (mean of 5.1 mg/dL) as compared to patients with lower UA plasma levels. Moreover, the former group of patients showed higher levels of cardiac troponin and CPK, and presented more often with multivessel disease and complex coronary stenosis (type C of Ellis classification). Even though monocentric and with limited sample size, the present study shows that plasma levels of UA and hs-CRP are elevated in ACS patients and are associated with a more severe coronary disease, suggesting a potential role of UA in the pathophysiology of acute coronary events.
MeSH term(s)	Humans ; C-Reactive Protein/analysis ; Acute Coronary Syndrome ; Uric Acid ; Endothelial Cells/chemistry ; Endothelial Cells/metabolism ; Retrospective Studies ; COVID-19 ; Coronary Artery Disease ; Biomarkers
Chemical Substances	C-Reactive Protein (9007-41-4) ; Uric Acid (268B43MJ25) ; Biomarkers
Language	English
Publishing date	2023-07-19
Publishing country	Italy
Document type	Journal Article
ZDB-ID	2454173-4
ISSN	1970-9366 ; 1828-0447
ISSN (online)	1970-9366
ISSN	1828-0447
DOI	10.1007/s11739-023-03360-2
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 6673: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Comparative effectiveness of Cangrelor in patients with acute coronary syndrome undergoing percutaneous coronary intervention: an observational investigation from the M.O.Ca. registry.

Pepe, Martino / Carulli, Eugenio / Larosa, Claudio / Napoli, Gianluigi / Nestola, Palma Luisa / Carella, Maria Cristina / Giordano, Salvatore / Tritto, Rocco / Bartolomucci, Francesco / Cirillo, Plinio / Zoccai, Giuseppe Biondi / Giordano, Arturo / Ciccone, Marco Matteo

Scientific reports

2023 Volume 13, Issue 1, Page(s) 10685

Abstract: Cangrelor, the first intravenous ... ...

Abstract	Cangrelor, the first intravenous P2Y
MeSH term(s)	Humans ; Acute Coronary Syndrome/surgery ; Retrospective Studies ; Percutaneous Coronary Intervention ; Registries
Chemical Substances	cangrelor (6AQ1Y404U7)
Language	English
Publishing date	2023-07-01
Publishing country	England
Document type	Observational Study ; Journal Article
ZDB-ID	2615211-3
ISSN	2045-2322 ; 2045-2322
ISSN (online)	2045-2322
ISSN	2045-2322
DOI	10.1038/s41598-023-37084-2
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article: Cangrelor in contemporary patients with ST-segment elevation myocardial infarction pretreated with Ticagrelor: Pharmacodynamic data from the POMPEII study.

Gargiulo, Giuseppe / Cirillo, Plinio / Sperandeo, Luca / Forzano, Imma / Castiello, Domenico Simone / Florimonte, Domenico / Simonetti, Fiorenzo / Paolillo, Roberta / Manzi, Lina / Spinelli, Alessandra / Spaccarotella, Carmen Anna Maria / Piccolo, Raffaele / Di Serafino, Luigi / Franzone, Anna / Capranzano, Piera / Valgimigli, Marco / Esposito, Giovanni

International journal of cardiology. Heart & vasculature

2024 Volume 50, Page(s) 101344

Abstract: Background: There are limited data to assess pharmacodynamic (PD) profiles of patients with STEMI undergoing primary percutaneous coronary intervention (PCI) and receiving cangrelor after pretreatment with ticagrelor.: Methods: The PharmacOdynaMic ... ...

Abstract	Background: There are limited data to assess pharmacodynamic (PD) profiles of patients with STEMI undergoing primary percutaneous coronary intervention (PCI) and receiving cangrelor after pretreatment with ticagrelor. Methods: The PharmacOdynaMic effects of cangrelor in PatiEnts wIth acute or chronIc coronary syndrome undergoing percutaneous coronary intervention (POMPEII) registry (NCT04790032) is a prospective study conducted at Federico II University of Naples enrolling all patients undergoing PCI receiving cangrelor at operator's discretion. PD assessments were performed with 3 assays: (1) the gold standard light transmittance aggregometry (LTA) (20- and 5-μM adenosine diphosphate [ADP] stimuli); (2) VerifyNow P2Y Results: We analyzed 13 STEMI patients pretreated with ticagrelor within 1 h at the time they underwent primary PCI receiving cangrelor. All patients showed low maximal platelet aggregation at 30-minute during cangrelor infusion, as well as at 3 h and 4-6 h (corresponding to 1 h and 2-4 h after stopping cangrelor infusion) with no cases of high residual platelet reactivity. These results were consistent with all assays. Conclusions: PD data show that in contemporary real-world STEMI patients pretreated within 1 h with ticagrelor undergoing primary PCI, adding cangrelor resulted in fast and potent platelet inhibition, thus suggesting that cangrelor may bridge the gap until ticagrelor reaches its effect.
Language	English
Publishing date	2024-01-23
Publishing country	Ireland
Document type	Journal Article
ZDB-ID	2818464-6
ISSN	2352-9067
ISSN	2352-9067
DOI	10.1016/j.ijcha.2024.101344
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: A comparison between radial artery compression devices for patent hemostasis after transradial percutaneous interventions.

Di Serafino, Luigi / Turturo, Maurizio / Larosa, Claudio / Scalamogna, Maria / Cirillo, Plinio / Vito Alessandro, Angelilli / Lanzone, Saverio / Bartolomucci, Francesco / Granata, Riccardo / Rea, Francesco Saverio / Piccolo, Raffaele / Franzone, Anna / Gargiulo, Giuseppe / Spaccarotella, Carmen Anna Maria / Stabile, Eugenio / Esposito, Giovanni

The Journal of invasive cardiology

2024

Abstract: Objectives: Patent hemostasis (PH) is essential for preventing radial artery occlusion (RAO) after trans-radial procedures; however, it remains unclear how it should be obtained. The aim of this multicenter randomized study was to evaluate whether the ... ...

Abstract	Objectives: Patent hemostasis (PH) is essential for preventing radial artery occlusion (RAO) after trans-radial procedures; however, it remains unclear how it should be obtained. The aim of this multicenter randomized study was to evaluate whether the use of an adjustable device (AD), inflated with a pre-determined amount of air (AoA), was more effective than a non-adjustable device (non-AD) for achieving PH, thereby reducing the incidence of RAO. Methods: We enrolled a total of 480 patients undergoing transradial procedure at 3 Italian institutions. Before the procedure, a modified Reverse Barbeau Test (mRBT) was performed in all patients to evaluate the AoA to be eventually inflated in the AD. After the procedure, patients were randomized into 2 groups: (1) AD Group, using TR-Band (Terumo) inflated with the pre-determined AoA; and 2) non-AD Group, using RadiStop (Abbott). An RBT was performed during compression to demonstrate the achievement of PH, as well as 24 hours later to evaluate the occurrence of RAO. Results: PH was more often obtained in the AD Group compared with the non-AD Group (90% vs 64%, respectively, P less than .001), with no difference in terms of bleedings. RAO occurred more often in the non-AD Group compared with the AD Group (10% vs 3%, respectively, P less than .001). Of note, mRBT was effective at guiding AD inflation and identifying high-risk patients in whom PH was more difficult to obtain. Conclusions: The use of AD, filled with a predetermined AoA, allowed PH significantly more often compared with non-AD, providing a significantly reduced incidence of RAO.
Language	English
Publishing date	2024-02-26
Publishing country	United States
Document type	Journal Article
ZDB-ID	1154372-3
ISSN	1557-2501 ; 1042-3931
ISSN (online)	1557-2501
ISSN	1042-3931
DOI	10.25270/jic/23.00302
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 3701: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 272: Show issues
Zs.MG 31: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

To top

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

Full text online

More links

Kategorien

Inter-library loan at ZB MED

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito